Pedisol DS0.225%+10%

Pedisol DS 0.225%+10% injection is an intravenous (IV) fluid used for:

• Replenishing body fluid in patients who are dehydrated or unable to take adequate fluids by mouth
• Providing sodium chloride and a source of carbohydrate calories intravenously
• Maintenance or replacement of fluid and electrolytes as required by the patient's clinical condition, as directed by the treating physician

Pedisol DS 0.225%+10% injection is marketed in several different concentration combinations (for example, varying strengths of dextrose such as 5% or 10%, and sodium chloride such as 0.9%, 0.45%, or 0.3%), and the generic name alone does not identify a single specific formulation. The exact concentration of dextrose and sodium chloride, container volume, and presentation vary by product; always confirm the specific concentration on the product label before use, since different concentrations are used for different clinical purposes.

Pedisol DS 0.225%+10% injection is a sterile intravenous fluid that combines a salt (electrolyte) solution with dextrose, a form of sugar. It is given by IV infusion to replace body fluids, supply sodium chloride, and provide a source of calories in patients who need intravenous hydration, such as during surgery, illness, or when oral intake is not possible. It is a hospital-administered fluid, not a self-administered medicine.

Therapeutic Class: Intravenous fluid and electrolyte replenisher

Sodium is the principal extracellular cation and helps maintain fluid balance, osmotic pressure, and the transmission of nerve impulses. Chloride, the major extracellular anion, closely follows sodium and helps maintain acid-base balance. Dextrose is metabolized to provide calories, spares body protein, and can help reduce ketosis when given in adequate amounts. This combination solution is used to correct or prevent fluid and electrolyte deficits while supplying a modest caloric source.

• Administered only by intravenous infusion, never by injection into muscle or under the skin
• Must be administered using sterile equipment and aseptic technique
• The solution should be visually inspected for particulate matter and discoloration before use
• Any additives should be checked for compatibility by a pharmacist before mixing into the solution
• Infusion rate should be monitored, particularly in patients at risk of fluid overload or glucose intolerance

Additives introduced into the solution may be incompatible; a pharmacist should be consulted before adding any medicine to the bag. In patients receiving corticosteroids or other drugs that promote sodium and fluid retention, concurrent use of sodium-containing solutions should be assessed carefully by the treating physician. Use in patients on insulin or other glucose-lowering therapy requires coordinated monitoring of blood glucose, as dextrose infusion can affect glycemic control.

Possible adverse effects

• Fluid overload, which can cause swelling (edema) of the extremities or, in severe cases, pulmonary edema
• Hyperglycemia (raised blood sugar), particularly with rapid infusion or in patients with impaired glucose tolerance
• Electrolyte imbalances such as low or high sodium or potassium levels
• Infusion-site reactions such as irritation, redness, or infection at the catheter site

Serious reactions

Hypersensitivity and infusion reactions, including anaphylaxis, have been reported and require immediate discontinuation of the infusion and medical attention.

Pregnancy

Intravenous fluid and electrolyte replacement with Pedisol DS 0.225%+10% solutions is commonly used in pregnancy when clinically indicated (for example, during labor, surgery, or illness), under medical supervision, with attention to fluid balance and blood glucose.

Breastfeeding

There is no specific concern regarding compatibility with breastfeeding for this type of intravenous fluid when used as directed by a healthcare professional; it is administered in a monitored clinical setting.

• Use with caution in patients with, or at risk of, fluid overload, heart failure, or impaired renal function, since sodium and fluid retention can worsen these conditions.
• Use with caution in patients with impaired glucose tolerance or diabetes, since dextrose infusion can raise blood glucose.
• Rapid or excessive infusion of dextrose can lead to hyperglycemia, and in severe cases coma; infusion rate should not exceed the patient's ability to utilize the dextrose load.
• Monitor serum electrolytes, fluid balance, and blood glucose periodically during prolonged or large-volume infusion.
• Central nervous system disease and renal impairment may increase the risk of a hyperosmolar hyperglycemic state with dextrose infusions.

Overinfusion (overhydration or solute overload) can cause fluid and electrolyte imbalance, including edema, worsened heart failure, and elevated blood sugar. If overdose or an adverse reaction occurs, the infusion should be stopped immediately, the patient reassessed, and appropriate corrective measures instituted, such as fluid restriction, diuretics, or insulin, as clinically indicated by the treating physician.

Store at controlled room temperature as specified on the product container; do not use if the overwrap or container seal is damaged, or if the solution appears cloudy, discolored, or contains particulate matter. Storage conditions may vary by manufacturer, concentration, and container type (glass or flexible plastic); always follow the specific product's labeling.

• Pediatric patients, especially neonates and low-birth-weight infants: Require careful selection of dextrose concentration and infusion rate due to increased risk of hyperglycemia or hypoglycemia.
• Renal impairment: Increased risk of hyperglycemia, hyponatremia, and fluid overload; requires close monitoring.
• Elderly patients: May be more susceptible to fluid overload and electrolyte disturbances; monitor closely.

Duration of IV fluid therapy depends entirely on the clinical indication and the patient's ongoing fluid, electrolyte, and caloric needs, as determined by the treating physician; it may range from a single infusion to continuous therapy over several days.

Drug Class: Parenteral fluid, electrolyte, and caloric replacement solution

Administered intravenously, the solution expands and replenishes extracellular fluid volume, supplies sodium and chloride ions needed for normal cell and nerve function, and provides dextrose that cells use as an energy source once metabolized.

Pedisol DS 0.225%+10% injection is used in pediatric patients, including neonates, as a source of fluid, electrolytes, and calories, but there is no single fixed pediatric dose; the volume and infusion rate are individualized based on the child's weight, clinical condition, and laboratory monitoring, with particular caution in neonates and low-birth-weight infants due to the risk of blood sugar swings.